Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1441-1445

  Tran, Thanh Huu ^a   Von Moltke, Lisa L ^a   Venkatakrishnan, Karthik ^b   Granda, Brian W ^c   Gibbs, Megan A ^b   Obach, R Scott ^b   Harmatz, Jerold S ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c Tufts University School of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DIAZEPAM; ENZYME INHIBITOR; FLUCONAZOLE; FLUVOXAMINE; ITRACONAZOLE; KETOCONAZOLE; NORFLUOXETINE; RITONAVIR; TEMAZEPAM; TERFENADINE; N DEMETHYLASE; PROTEIN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

STAPHYLOCOCCUS PHAGE 3A;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEINS;

EID: 0036891924     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1441     Document Type: Article

References (31)

1. Andersson T, Miners JO, Veronese ME, and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137.
2. Erve JCL, Dandeneau AA, Patten C, Stresser DM, and Crespi CL (2000) Metabolic stability of CYP isoform selective inhibitors in the presence of human liver microsomes. 13th International Symposium on Microsomes and Drug Oxidation. Stressa, Italy.
3. Gascon M-P and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
4. Ghosal A, Satoh H, Thomas P, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
5. Gibbs MA, Kunze KL, Howald WN, and Thummel KE (1999a) Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27:596-599.
6. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999b) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
7. Greenblatt DJ, Divoll M, Moschitto LJ, and Shader RI (1981) Electron-capture gas chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. J Chromatogr 225:202-207.
8. Hargreaves JA, Jezequel S, and Houston JB (1994) Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38:175P.
9. Jung F, Richardson TH, Raucy JL, and Johnson EF (1997) Diazepam metabolism by cDNA-expressed human 2C P450s: Identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metab Dispos 25:133-139.
10. Kalvass JC, Tess DA, Giragossian C, Linhares MC, and Maurer TS (2001) Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metab Dispos 29:1332-1336.
11. McLure JA, Miners JO, and Birkett DJ (2000) Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
12. Obach RS (1997) Nonspecific binding to microsomes. Drug Metab Dispos 25:1359-1369.
13. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
14. Obach RS (1996) The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions and implications for in vitro-in vivo correlations. Drug Metab Dispos 24:1047-1049.
15. Ono S, Hatanaka T, Miyazawa S, Tsutui M, Aoyama T, Gonzalez FJ, and Satoh T (1996) Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 11:1155-1166.
16. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
17. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000a) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
18. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2000b) Effects of the antifungal agents on oxidative drug metabolism in humans: Clinical relevance. Clin Pharmacokinet 38:111-180.
19. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001a) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
20. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001b) Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
21. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2000c) Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 293:343-350.
22. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, and Shader RI (1994a) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
23. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, and Shader RI (1994b) Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.
24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, and Shader RI (1995) Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Phychopharmacol 15:125-131.
25. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, and Shader RI (1998a) Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharm Pharmacol Commun 4:443-445.
26. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, and Shader RI (1998b) Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 38:106-111.
27. von Moltke LL, Greenblatt DJ, Harmatz JS, and Shader RI (1993) Alprazolam metabolism in vitro: Studies of human, monkey, mouse and rat liver microsomes. Pharmacology 47:268-276.
28. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996a) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
29. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and Shader RI (1996b) Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine and by azole antifungal agents. J Clin Pharmacol 36:783-791.
30. Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, and Kivistö KT (1999) Midazolam α-hydroxylation by human liver microsomes in vitro: Inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol 85:157-161.
31. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res 11:921-924.